ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 302

Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy:  1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial

Christopher T. Ritchlin1, Iain B. McInnes2, Arthur Kavanaugh3, Lluis Puig4, Proton Rahman5, Carrie Brodmerkel6, Shu Li6, Yaung-Kaung Shen6, Mittie K. Doyle6, Alan M. Mendelsohn7 and Alice B. Gottlieb8, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3University of California, San Diego, La Jolla, CA, 4Universitat Autònoma de Barcelona, Barcelona, Spain, 5Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 6Janssen Research & Development, LLC., Spring House, PA, 7Immunology, Janssen Research & Development, LLC., Spring House, PA, 8Tufts Medical Center, Boston, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Biologics and psoriatic arthritis

Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Ustekinumab (UST) has demonstrated substantial efficacy and an acceptable safety profile, and is approved for use, in treating moderate-to-severe psoriasis. UST has also demonstrated efficacy in pts with active psoriatic arthritis (PsA) at wk24 in the Phase 3, multicenter, PBO-controlled PSUMMIT2 trial. Results through wk52 PSUMMIT 2 are presented herein.

Methods: 312 adults with active PsA were randomized to UST 45mg or 90mg at wk0, wk4, and q12w or PBO at wks0, 4, and 16 followed by crossover to UST 45mg at wk24, wk28, and wk40. Randomization was stratified by site, weight (≤100kg, >100kg) and baseline MTX use, and pts previously treated with biologic anti-TNF agents were eligible. At wk16, pts with <5% improvement in both tender/swollen joint counts entered blinded early escape (PBO→UST 45mg, 45mg→90mg, 90mg→90mg). The primary endpoint was ACR20 at wk24. Secondary endpoints were HAQ-DI, ACR50, ACR70, and ≥75% improvement in the Psoriasis Area and Severity Index (PASI75).

Results: Anti-TNF-experienced pts had more active disease at baseline than anti-TNF-naïve pts.  More UST (43.8%-combined, 43.7%-45mg, 43.8%-90mg) than PBO (20.2%) treated pts had ACR20 at wk24 (all P<0.001). Significant treatment differences were also observed for ACR50 and PASI75 response  at wk24 (table). Efficacy was sustained through wk52. At wk52, 51% and 44% of pts who were and were not, respectively, receiving MTX at baseline had ACR20. UST efficacy at wk52 was more robust in anti-TNF-naïve (ACR20 59-73%) than anti-TNF-experienced (37-41%) pts and pts who had previously received 1 (50-55%) vs. 2 (13-39%) or ≥3 (13-30%) anti-TNF agents. UST was generally well tolerated, with no deaths or tuberculosis and similar rates of AEs (78.6%-45mg, 77.9%-90mg), serious AEs (5.8%-45mg, 5.8%-90mg), and AEs leading to discontinuation (5.8%-45mg, 3.8%-90mg) reported across doses through wk60.  Two pts, both anti-TNF-experienced, had malignancies (breast cancer-45mg, squamous cell carcinoma-90mg); 2/287 (0.7%) of UST-treated pts (both 90mg) had serious infections. Three pts (2-45mg, 1-90mg) had major adverse cardiovascular events (myocardial infarctions) through wk60, all had multiple cardiovascular risk factors and prior anti-TNF experience.

 

Conclusion: Both UST doses (45/90 mg q12w) yielded significant and sustained improvements in PsA signs/symptoms with favorable and comparable safety profiles.  UST was effective in both anti-TNF-naïve and anti-TNF-experienced pts, with greater efficacy in anti-TNF naïve pts and anti-TNF-experienced pts previously treated with 1 or 2 anti-TNF agents.

 Table. Summary of efficacy among randomized PsA pts

(N)

Placebo

(104)

UST 45 mg

(103)

UST 90 mg

(105)

Combined UST

(208)

BASELINE

 

 

 

 

Anti-TNF experienced pts

 

 

 

 

Tender(0-68)/swollen(0-66) joints

24/11

24/15

26/13

25/14

Physician/Pt global disease (0-10 VAS)/HAQ-DI (0-3)

7.2/6.1/1.31

7.7/6.6/1.44

7.6/6.9/1.56

7.6/6.8/1.50

Anti-TNF naïve pts

 

 

 

 

Tender/swollen joints

20/10

19/12

19/10

19/11

Physician/Patient global disease/HAQ-DI

7.0/6.1/1.13

6.4/5.7/1.25

6.6/5.5/1.06

6.6/5.6/1.13

WEEK 24 EFFICACY

 

 

 

 

ACR20/ACR50/ACR70

20.2/6.7/2.9%

43.7***/17.5*/6.8%

43.8***/22.9**/8.6%

43.8***/20.2**/7.7%

PASI751

5.0%

51.3%***

55.6%***

53.4%***

WEEK 52 EFFICACY (N)

Placebo→UST 45 mg, (77)

UST 45 mg

(94)

UST 90 mg

(95)

Combined UST

(189)

ACR20/ACR50/ACR70

55.8/28.6/15.6%

46.8/27.7/12.8%

48.4/26.3/17.9%

47.6/27.0/15.3%

ACR20 by baseline MTX use (Yes / No)

51.2/61.1%

46.0/47.7%

56.5/40.8%

51.0/44.1%

ACR20 – anti-TNF-naïve/exper

73.0/40.0%

60.0/37.0%

58.5/40.7%

59.3/38.9%

ACR20 by no. of prior anti-TNF agents (1 / 2 / ≥3)

54.5/12.5/30.0%

52.4/25.0/29.4%

50.0/38.9/12.5%

51.0/32.4/24.0%

% improve dactylitis/enthesitis1

33.3/100.0%

36.7/95.0%

60.0/90.9%

50.0/95.0%

PASI752

56.1%

56.5%

64.4%

60.6%

*, **, *** indicate p < 0.05, 0.01, 0.001, respectively, versus placebo. Data are reported as % of pts or median.

1Among patients with dactylitis or enthesitis at baseline. 2Among pts with ≥ 3% body surface area psoriasis involvement at baseline (mean PASI scores at baseline were 11.3 for placebo, 13.4 for UST 45 mg, and 12.1 for UST 90 mg). 

ACR=American College of Rheumatology, HAQ-DI=Health Assessment Questionnaire-Disability Index, PASI=Psoriasis Area and Severity Index, TNF=tumor necrosis factor, UST=ustekinumab, VAS=visual analogue scale

 


Disclosure:

C. T. Ritchlin,

Amgen, Janssen, UCB, Abbott (AbbVie), Regeneron,

5,

Amgen, Janssen, UCB,

2;

I. B. McInnes,

Novartis, Janssen Research & Development, LLC.,

8,

UCB,

9;

A. Kavanaugh,

Janssen Research & Development, LLC.,

9;

L. Puig,

Abbvie, Amgen, Janssen, Lilly, Novartis, Pfizer, VBL,

2,

Celgene, Abbvie, Janssen, Novartis, MSO, Pfizer, Lex Pharma,

5;

P. Rahman,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

5,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

9;

C. Brodmerkel,

Janssen Research & Development, LLC.,

3;

S. Li,

Janssen Research & Development, LLC.,

3;

Y. K. Shen,

Janssen Research & Development, LLC.,

3;

M. K. Doyle,

Janssen Research & Development, LLC.,

3;

A. M. Mendelsohn,

Janssen Research & Development, LLC.,

3;

A. B. Gottlieb,

Janssen, Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia,

2,

Astellas, Janssen, Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs. (Abbvie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Li,

5.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/maintenance-of-efficacy-and-safety-of-ustekinumab-in-patients-with-active-psoriatic-arthritis-despite-prior-conventional-nonbiologic-and-anti-tnf-biologic-therapy-1%e2%80%91year-results-of-a-ph/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology